Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/14287
Title: Skeletal muscle disorders of glycogenolysis and glycolysis
Authors: Godfrey, R
Quinlivan, R
Keywords: Science & Technology;Life Sciences & Biomedicine;Clinical Neurology;Neurosciences & Neurology;Disease type-iii;Phosphoglycerate kinase-deficiency;Phosphoglucomutase 1 deficiency;Polyglucosan body myopathy;Beta-enolase deficiency;All-cause mortality;Mcardle-disease;Phosphofructokinase deficiency;Phosphorylase-kinase;Storage diseases
Issue Date: 2016
Publisher: Nature Publishing Group
Citation: Nature Reviews Neurology, 2016, 12 (7), pp. 393 - 402 (10)
Abstract: Skeletal muscle disorders of glycogenolysis and glycolysis account for most of the conditions collectively termed glycogen storage diseases (GSDs). These disorders are rare (incidence 1 in 20,000–43,000 live births), and are caused by autosomal or X-linked recessive mutations that result in a specific enzyme deficiency, leading to the inability to utilize muscle glycogen as an energy substrate. McArdle disease (GSD V) is the most common of these disorders, and is caused by mutations in the gene encoding muscle glycogen phosphorylase. Symptoms of McArdle disease and most other related GSDs include exercise intolerance, muscle contracture, acute rhabdomyolysis, and risk of acute renal failure. Older patients may exhibit muscle wasting and weakness involving the paraspinal muscles and shoulder girdle. For patients with these conditions, engaging with exercise is likely to be beneficial. Diagnosis is frequently delayed owing to the rarity of the conditions and lack of access to appropriate investigations. A few randomized clinical trials have been conducted, some focusing on dietary modification, although the quality of the evidence is low and no specific recommendations can yet be made. The development of EUROMAC, an international registry for these disorders, should improve our knowledge of their natural histories and provide a platform for future clinical trials.
URI: https://bura.brunel.ac.uk/handle/2438/14287
DOI: https://doi.org/10.1038/nrneurol.2016.75
ISSN: 1759-4758
1759-4766
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.doc221 kBMicrosoft WordView/Open


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.